CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Foehr David reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. senior vice president of finance and principal accounting officer David Foehr reported equity compensation awards. He received a grant of options to buy 36,750 shares of common stock at $18.50 per share, expiring on April 1, 2036, and 22,050 restricted stock units.
The option shares will vest on each quarterly anniversary from May 20, 2026, as long as he continues his service with the company on each vesting date. Following these grants, Foehr directly holds 39,600 shares of common stock. These are compensation-related awards, not open-market purchases or sales.
Manni Joseph S. reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. reported that Chief Revenue Officer Joseph S. Manni received equity compensation on April 1, 2026. He was granted a stock option to buy 51,227 shares of common stock at $18.50 per share, expiring on April 1, 2036, and a separate grant of 30,736 shares of common stock as restricted stock units. The option vests on each quarterly anniversary from May 20, 2026, subject to his continued service. After these awards, he directly owns 57,669 shares of common stock.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported a mix of option exercises, stock sales, and new equity awards. On April 1, he exercised stock options for a total of 11,112 shares of common stock at exercise prices of $2.24 and $4.70 per share, then sold the same 11,112 shares in open-market transactions at prices around $18.53–$18.58. The filing notes these trades were made under a Rule 10b5-1 trading plan. Woo also received new grants: 51,227 stock options at an exercise price of $18.50 and 30,736 restricted stock units, bringing his direct common stock holdings to 197,648 shares after the transactions.
CBLL reported proposed resale transactions under a Form 144. The filing lists securities to be sold on 04/01/2026 arising from option grants dated 07/07/2021 (1,472 shares) and 02/16/2023 (9,640 shares). The filing also records prior open-market sales by Raymond Woo: 01/02/2026 (11,112 shares for $235,228.09), 02/02/2026 (11,112 shares for $228,408.70), 03/02/2026 (11,112 shares for $202,831.12), and 02/23/2026 (705 shares for $13,955.12). The broker on the notice is Fidelity Brokerage Services LLC.
Ceribell, Inc. President and CEO Chao Xingjuan reported exercising stock options to acquire a total of 55,628 shares of common stock. She exercised options for 36,628 shares at an exercise price of $2.24 per share and 19,000 shares at $3.65 per share.
After these transactions, she holds 766,792 shares of common stock directly. An additional 369,088 shares are held indirectly by the ACP 2021 Trust, where she is a co-trustee and may be deemed to share beneficial ownership, while disclaiming beneficial ownership except to the extent of her pecuniary interest.
Ceribell, Inc. Senior VP, Finance and PAO David Foehr exercised stock options and sold shares in the company. On March 3, 2026, he exercised options for 3,403 and 1,157 shares of common stock at $4.70 per share and then sold the same totals, 4,560 shares of common stock, at $17.80 per share in open-market transactions. After these trades, he directly held 17,550 shares of Ceribell common stock. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025, and the underlying options vest over time through monthly installments after an initial 25% vesting on May 31, 2023.
Ceribell, Inc. director Rebecca B. Robertson reported an open-market sale of 827 shares of common stock at $17.80 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, and she now holds 18,749 shares directly.
Ceribell, Inc. President and CEO Xingjuan Chao exercised stock options and sold shares in a planned series of trades. She exercised options covering 1,446 and 23,554 shares of common stock at an exercise price of $4.70 per share, then sold a total of 39,000 common shares in open-market transactions on March 3, 2026 at weighted average prices around $17.45–$17.46 per share under a Rule 10b5-1 trading plan. Following these transactions, she holds 711,164 shares directly and has indirect exposure to 369,088 additional shares held by the ACP 2021 Trust, where she is a co-trustee and disclaims beneficial ownership beyond her pecuniary interest.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported a set of option exercises and related share sales in Ceribell stock. On March 2, 2026, he exercised multiple stock options to acquire common shares and then sold 11,112 shares of common stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025. The reported sale prices were based on weighted-average prices within ranges from $18.10 to $18.41 per share. After these transactions, Woo directly held 166,912 shares of Ceribell common stock.
CBLL reports Form 144 notice of affiliate sales. The filing lists multiple sales by Xingjuan Chao, including 25,000 shares on 12/04/2025 for 470,532.50, 79,000 shares on 01/05/2026 for 1,680,124.43, 39,000 shares on 02/04/2026 for 786,392.36, and 2,084 shares on 02/23/2026 for 41,251.74.
The form also lists planned option-related sales and grants with dates and share counts, including 9,821 shares (09/25/2024), 4,179 shares (05/15/2025), and 25,000 shares (03/03/2026).